DEK and acute lymphoblastic leukemia: SET-NUP214 has been mostly reported in T-ALL and rarely in AML and AUL, while DEK-NUP214 has been exclusively reported in myelodysplastic syndrome (MDS) and AML, indicating that distinct cellular pathways drive leukemogenic progression in patients with either fusion transcript [50,54].